Q-omics provides the consensus-scored FAM138A profile across patient tissues and cancer cell-line models. FAM138A expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, FAM138A is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, FAM138A RNA expression shows 1,698 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, HNSC, and STAD as cancer lineages where FAM138A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM138A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM138A survival associations across molecular data types. FAM138A RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM138A RNA expression–survival associations across cancer types. High FAM138A expression shows unfavorable associations in LUSC, MESO, LGG, PAAD and UVM, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify ESCA as the clearest survival context for FAM138A RNA expression.
This table summarizes FAM138A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM138A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM138A shows lower tumor expression in LUSC and higher tumor expression in HNSC. The HNSC box plot shows higher FAM138A RNA expression in tumor versus normal tissue (log2 FC = +0.008, t-test p = .010).
This table shows molecular features associated with FAM138A in patient tissues and cancer cell lines. In patient samples, FAM138A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
